444 related articles for article (PubMed ID: 18367104)
1. Pathobiology and prognosis of chromophobe renal cell carcinoma.
Klatte T; Han KR; Said JW; Böhm M; Allhoff EP; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Urol Oncol; 2008; 26(6):604-9. PubMed ID: 18367104
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
3. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
4. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
[TBL] [Abstract][Full Text] [Related]
7. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
8. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients.
Gudbjartsson T; Hardarson S; Petursdottir V; Thoroddsen A; Magnusson J; Einarsson GV
Eur Urol; 2005 Oct; 48(4):593-600. PubMed ID: 15964127
[TBL] [Abstract][Full Text] [Related]
9. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H
Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125
[TBL] [Abstract][Full Text] [Related]
10. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
11. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
[TBL] [Abstract][Full Text] [Related]
13. Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma.
Lee SE; Byun SS; Oh JK; Lee SC; Chang IH; Choe G; Hong SK
J Urol; 2006 Oct; 176(4 Pt 1):1332-7; discussion 1337-8. PubMed ID: 16952624
[TBL] [Abstract][Full Text] [Related]
14. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma.
Jung EJ; Lee HJ; Kwak C; Ku JH; Moon KC
Urology; 2009 Jan; 73(1):137-41. PubMed ID: 18950844
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience.
Klatte T; Wunderlich H; Patard JJ; Kleid MD; Lam JS; Junker K; Schubert J; Böhm M; Allhoff EP; Kabbinavar FF; Crepel M; Cindolo L; De La Taille A; Tostain J; Mejean A; Soulie M; Bellec L; Bernhard JC; Ferriere JM; Pfister C; Albouy B; Colombel M; Zisman A; Belldegrun AS; Pantuck AJ
BJU Int; 2007 Jul; 100(1):21-5. PubMed ID: 17433034
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
[TBL] [Abstract][Full Text] [Related]
19. Cystic renal cell carcinoma: biology and clinical behavior.
Han KR; Janzen NK; McWhorter VC; Kim HL; Pantuck AJ; Zisman A; Figlin RA; Dorey FJ; Said JW; Belldegrun AS
Urol Oncol; 2004; 22(5):410-4. PubMed ID: 15464922
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
